Version history

{
  "content_md": "# Multiple Sclerosis (MS)\n\n## Overview\n\nMultiple Sclerosis is a chronic, immune-mediated, demyelinating disease of the central nervous system (CNS) that represents the leading cause of non-traumatic disability in young adults worldwide. The disease is characterized by focal inflammatory demyelination, widespread neurodegeneration, and progressive neurological impairment affecting motor, sensory, and cognitive functions. MS typically presents in early adulthood (ages 20–40), with a female-to-male ratio of approximately 3:1, suggesting hormonal or sex-linked immune factors play a significant role in pathogenesis.\n\nThe disease involves an aberrant autoimmune response in which autoreactive T cells and B cells cross the blood-brain barrier and attack myelin sheath proteins, including myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP). This immune assault triggers a cascade of inflammatory events, including microglial activation, cytokine release (IFN-γ, IL-17, TNF-α), and recruitment of peripheral immune cells. The resulting demyelination disrupts saltatory conduction along axons, leading to conduction block and neurological deficits. Over time, repeated inflammatory episodes lead to axonal transection, neuronal loss, and the accumulation of irreversible disability—a transition that marks the shift from relapsing-remitting to secondary progressive MS.\n\nGlobally, MS affects approximately 2.8 million people, with prevalence varying significantly by latitude (higher in northern latitudes), suggesting a potential role for vitamin D deficiency and environmental factors. The disease course typically begins with a relapsing-remitting phase characterized by discrete neurological episodes (relapses) with partial or complete recovery (remissions). Within 10–20 years, approximately 80% of patients enter a secondary progressive phase with steady deterioration. A minority (~15%) follow a primary progressive course from onset, marked by gradual worsening without clear relapses.\n\n## Capabilities/Features\n\n**Clinical Phenotypes**: MS manifests in four principal clinical courses. Relapsing-Remitting MS (RRMS) accounts for ~85% of initial diagnoses, featuring discrete attacks with partial recovery. Secondary Progressive MS (SPMS) represents the later phase of RRMS with gradual disability accumulation. Primary Progressive MS (PPMS) shows steady progression from disease onset without relapses (~10–15% of patients). Progressive-Relapsing MS is a rare variant with progressive disease punctuated by acute relapses.\n\n**Neuropathological Hallmarks**: The disease is characterized by MS plaques—focal areas of myelin loss with relative preservation of axons initially. Active plaques display perivascular immune infiltration (CD4+ and CD8+ T cells, B cells, macrophages), myelin debris, and reactive gliosis. Chronic plaques show hypocellularity, dense glial scarring, and axonal degeneration. Cortical demyelination and gray matter atrophy are increasingly recognized as drivers of progressive disability.\n\n**Diagnostic Biomarkers**: MRI reveals T2 hyperintense lesions (particularly periventricular, juxtacortical, and infratentorial), gadolinium-enhancing lesions indicating active inflammation, and brain atrophy. Cerebrospinal fluid analysis typically shows oligoclonal bands (IgG) in ~90% of patients and elevated IgG index. Serum neurofilament light chain (NfL) serves as a biomarker of neuronal injury.\n\n**Treatment Approaches**: Disease-modifying therapies target the immune axis. Interferon-beta and glatiramer acetate modulate immune function. Fingolimod, siponimod, and ozanimod block S1P receptor trafficking. Natalizumab and alemtuzumab prevent immune cell CNS infiltration. Ocrelizumab and ofatumumab deplete B cells via CD20. High-efficacy approaches like hematopoietic stem cell transplantation are reserved for treatment-refractory cases.\n\n## Relevance to Neurodegeneration Research\n\nMS serves as a critical model for understanding the interplay between neuroinflammation and neurodegeneration across multiple scales. Research on MS has illuminated how adaptive immune responses, microglial activation, and complement cascades contribute to progressive neuroaxonal injury—mechanisms directly relevant to [Alzheimer's Disease] and [Parkinson's Disease], where similar microglial and inflammatory pathways drive pathology.\n\nThe disease has proven instrumental in dissecting the role of the gut microbiome in shaping CNS autoimmunity, as germ-free mice show ameliorated disease in MS models like experimental autoimmune encephalomyelitis (EAE). This microbiome-brain-immune axis research has informed investigations into [Amyotrophic Lateral Sclerosis (ALS)], where gut dysbiosis and microbial metabolites influence disease progression.\n\nStudies of remyelination failure in MS have identified oligodendrocyte progenitor cell (OPC) dysfunction as a central mechanism, yielding insights into myelin repair that may benefit conditions characterized by oligodendrocyte loss. The identification of gradual axonal loss as the substrate for progression has shifted research from purely anti-inflammatory strategies toward neuroprotective and remyelination-promoting approaches—priorities shared by neurodegeneration research broadly.\n\nMS research has also advanced understanding of the blood-brain barrier in neuroinflammatory states, informing therapeutic strategies for CNS drug delivery relevant to all neurodegenerative conditions. Finally, the availability of human tissue through MS brain banks has enabled transcriptomic studies (single-nucleus RNA sequencing) revealing disease-state microglial and astrocyte signatures that parallel those observed in other neurodegenerative diseases.\n\n## Related Entities\n\n**Genes**: [HLA-DRB1*15:01] — strongest genetic risk allele for MS, part of the MHC class II locus; [IL2RA] — interleukin-2 receptor alpha, T cell activation gene implicated in MS risk; [IL7R] — interleukin-7 receptor alpha, affects T cell homeostasis; [PTGER4] — prostaglandin E2 receptorEP4, involved in immune regulation; [TYK2] — tyrosine kinase 2, JAK-STAT signaling in immune cells.\n\n**Proteins and Pathways**: [Myelin Oligodendrocyte Glycoprotein (MOG)] — target of demyelinating antibodies; [Myelin Basic Protein (MBP)] — major myelin component attacked in MS; [Aquaporin-4 (AQP4)] — target in neuromyelitis optica spectrum disorder, a related demyelinating condition; [S1P Receptor] — target of fingolimod/siponimod, regulates lymphocyte egress from lymph nodes; [MBP] — myelin basic protein.\n\n**Diseases**: [Neuromyelitis Optica Spectrum Disorder (NMOSD)] — AQP4-IgG seropositive demyelinating disease; [Acute Disseminated Encephalomyelitis (ADEM)] — monophasic demyelinating encephalitis, often post-infectious; [MOG-Associated Encephalomyelitis] — distinct demyelinating entity with MOG antibodies; [Creutzfeldt-Jakob Disease] — although prion-mediated, shows overlapping MRI and clinical features requiring differential diagnosis.\n\n**Pathways**: [Type 1 T Helper Cell (Th1) Response] — IFN-γ-producing cells driving CNS inflammation; [Type 17 T Helper Cell (Th17) Response] — IL-17-producing cells implicated in breach of blood-brain barrier; [Complement Cascade] — C1q and C3 activation contribute to demyelination and axonal injury; [JAK-STAT Signaling] — activated in immune cells, therapeutic target.\n\n## References\n\n1. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26(3):339-347. doi:10.1111/ene.13819\n2. Filippi M, et al. Multiple sclerosis: Nat Rev Dis Primers. 2018;4(1):43. doi:10.1038/s41572-018-0041-4\n3. Reich DS, et al. Multiple Sclerosis. N Engl J Med. 2018;378(2):169-180. doi:10.1056/NEJMcp1400483\n4. Hauser SL, et al. B-cell depletion in multiple sclerosis. N Engl J Med. 2023;388(19):1777-1792. doi:10.1056/NEJMoa2203867\n5. Baecher-Allan C, et al. Regulatory T cells in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9(3):a029108. doi:10.1101/cshperspect.a029108\n6. Lubetzki C, et al. Remyelination in multiple sclerosis: from biology to therapy. Nat Rev Neurosci. 2021;22(11):637-648. doi:10.1038/s41583-021-00506-0\n7.Dendrou CA, et al. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545-558. doi:10.1038/nri3901\n8. Kuhlmann T, et al. Multiple sclerosis pathology. Handb Clin Neurol. 2020;171:109-123. doi:10.1016/B978-0-444-64229-3.00006-4",
  "entity_type": "disease"
}

{
  "content_md": "# Multiple Sclerosis (MS)\n\n## Overview\n\nMultiple Sclerosis is a chronic, immune-mediated, demyelinating disease of the central nervous system (CNS) that represents the leading cause of non-traumatic disability in young adults worldwide. The disease is characterized by focal inflammatory demyelination, widespread neurodegeneration, and progressive neurological impairment affecting motor, sensory, and cognitive functions. MS typically presents in early adulthood (ages 20-40), with a female-to-male ratio of approximately 3:1, suggesting hormonal and genetic factors play significant roles in disease susceptibility. The global prevalence exceeds 2.8 million individuals, with higher incidence in temperate climates and populations of European ancestry, though the reasons for this geographic distribution remain incompletely understood.\n\nThe pathological hallmark of MS is the formation of discrete plaques (lesions) in the CNS white and grey matter, where immune cells infiltrate and destroy the myelin sheath that insulates neuronal axons. This demyelination disrupts saltatory conduction along affected nerve fibers, leading to impaired signal transmission and the diverse neurological symptoms characteristic of the disease. Beneath the inflammatory lesions, significant axonal degeneration and neuronal loss occur even in early disease stages, contributing to irreversible disability accumulation. The disease course varies substantially among individuals, with the majority initially experiencing a relapsing-remitting pattern characterized by discrete neurological episodes followed by periods of partial or complete recovery.\n\n## Capabilities/Features\n\nMS manifests through several clinical phenotypes that reflect distinct pathophysiological mechanisms. Relapsing-remitting MS (RRMS) accounts for approximately 85% of initial diagnoses and features clearly defined relapses with periods of remission. Secondary progressive MS develops in most RRMS patients over time, characterized by steady neurological decline with or without occasional relapses. Primary progressive MS (PPMS), affecting 10-15% of patients, shows continuous worsening from disease onset without early relapses. These phenotypes likely reflect different contributions of adaptive immune activation versus innate immune mechanisms and neurodegenerative processes.\n\nThe immune pathophysiology of MS involves both peripheral T-cell and B-cell responses as well as CNS-resident immune mechanisms. CD4+ and CD8+ T cells recognize myelin antigens including myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG), driving inflammation within the CNS. B cells produce oligoclonal immunoglobulin G in cerebrospinal fluid, reflecting their accumulation and activation within the CNS compartment. Microglial cells and astrocytes become persistently activated in MS lesions, releasing pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ) that perpetuate tissue damage. The complement system also participates in myelin destruction, with C9 terminal complex deposition observed in active demyelinating lesions.\n\nNeurodegeneration in MS involves multiple interconnected mechanisms including mitochondrial dysfunction, oxidative stress, and excitotoxicity. Damaged axons exhibit impaired adenosine triphosphate (ATP) production due to mitochondrial injury, rendering them vulnerable to degeneration. Reactive oxygen and nitrogen species accumulate in MS lesions, causing oxidative damage to lipids, proteins, and nucleic acids. Glutamate excitotoxicity contributes to oligodendrocyte death and axonal injury through excessive calcium influx via ionotropic glutamate receptors. These degenerative processes may operate independently of acute inflammation in progressive disease stages, explaining why immunomodulatory therapies show limited efficacy in non-relapsing progressive MS.\n\n## Relevance to Neurodegeneration Research\n\nMS research has provided critical insights into neuroimmune interactions that inform understanding of other neurodegenerative conditions. The identification ofEBV infection as a necessary but insufficient risk factor for MS development has illuminated how viral triggers may initiate chronic immune-mediated CNS damage, a paradigm with implications for understanding how infections might contribute to [Alzheimer's Disease] and [Parkinson's Disease] pathogenesis. The mechanisms of demyelination and remyelination in MS lesions parallel processes relevant to other white matter disorders and to understanding CNS repair capacity more broadly.\n\nThe progressive neurodegenerative phase of MS shares mechanistic features with other age-related neurological conditions. Mitochondrial dysfunction and oxidative stress in MS lesions resemble pathways implicated in [Amyotrophic Lateral Sclerosis (ALS)] and [Alzheimer's Disease], suggesting convergent mechanisms of neuronal injury across disparate conditions. Neuroaxonal degeneration in MS involves pathways including caspase-mediated apoptosis, necroptosis, and ferroptosis, which are active in multiple neurodegenerative diseases. The study of how inflammatory mechanisms interact with neurodegeneration in MS has therefore informed broader understanding of how immune activation contributes to neuronal death in the aging nervous system.\n\nClinical and translational research in MS has pioneered outcome measures and therapeutic approaches subsequently applied across neurodegeneration research. Magnetic resonance imaging (MRI) techniques developed to visualize MS lesions, including T2-weighted imaging, gadolinium-enhanced T1-weighted imaging, and advanced quantitative measures like magnetization transfer imaging and diffusion tensor imaging, have become standard tools for monitoring neurodegeneration in other conditions. The success of disease-modifying therapies targeting immune pathways in MS, including monoclonal antibodies against CD20 (ocrelizumab), CD52 (alemtuzumab), and integrin subunits (natalizumab), has validated immunomodulation as a therapeutic strategy with potential applications in other neuroimmune conditions.\n\n## Related Entities\n\n- **Genes/Proteins**: HLA-DRB1, IL2RA, IL7R, MBP, PLP, MOG, TNF,玄NT5A, VIM (Vimentin)\n- **Diseases/Conditions**: [Clinically Isolated Syndrome], [Neuromyelitis Optica Spectrum Disorder], [Acute Disseminated Encephalomyelitis], [Alzheimer's Disease], [Parkinson's Disease], [Amyotrophic Lateral Sclerosis (ALS)]\n- **Pathways**: T-cell receptor signaling, cytokine signaling, complement cascade, mitochondrial electron transport chain, oxidative stress response\n- **Therapeutics**: Interferon-beta, Glatiramer acetate, Fingolimod, Ocrelizumab, Natalizumab, Siponimod\n\n## References\n\n- Reich DS, et al. Multiple Sclerosis. N Engl J Med. 2018;378(2):169-180.\n- Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27-40.\n- Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018;97(4):742-768.\n- Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive MS: the unraveling of the puzzle. Neurology. 2017;89(13):1388-1396.",
  "entity_type": "disease"
}

{
  "content_md": "# Multiple Sclerosis (MS)\n\n## Overview\n\nMultiple Sclerosis is a chronic, immune-mediated, demyelinating disease of the central nervous system (CNS) that represents the leading cause of non-traumatic disability in young adults worldwide. The disease is characterized by focal inflammatory demyelination, widespread neurodegeneration, and progressive neurological impairment affecting motor, sensory, and cognitive functions. MS typically presents in early adulthood (ages 20-40), with a female-to-male predominance of approximately 3:1, suggesting significant hormonal and genetic influences on disease susceptibility.\n\nThe pathophysiology of MS involves a complex interplay between autoreactive T cells, B cells, and myeloid cells that breach the blood-brain barrier and attack CNS antigens. Myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and myelin-associated oligodendrocyte glycoprotein (MAG) are among the target antigens recognized by pathogenic immune cells. This immune attack triggers a cascade of events including oligodendrocyte death, myelin sheath destruction, and subsequent axonal degeneration. The disease follows either a relapsing-remitting course (RRMS) in approximately 85% of patients initially, or a progressive trajectory (primary progressive MS), with many patients eventually transitioning to secondary progressive disease.\n\n## Capabilities/Features\n\nMultiple Sclerosis demonstrates several hallmark pathological features that distinguish it from other neurological conditions. The disease creates distinct lesion patterns characterized by perivenous inflammatory infiltrates composed of CD4+ and CD8+ T lymphocytes, macrophages, and B cells. These inflammatory foci are associated with complement activation and antibody-mediated demyelination.\n\nThe disease exhibits several distinct phases of pathological progression. Early relapsing phases are dominated by peripherally-derived adaptive immune responses, while progressive phases involve compartmentalized inflammation within the CNS, microglial activation, and chronic oxidative injury. Neuroaxonal degeneration occurs early in disease course and correlates with irreversible disability accumulation. Cortical demyelination and gray matter involvement become increasingly prominent in later disease stages.\n\nMS demonstrates remarkable heterogeneity in clinical presentation, radiological features, and pathological patterns. The four recognized pathological patterns (types I-IV) defined by Lucchinetti et al. indicate that MS may represent a spectrum of distinct disease entities with different underlying mechanisms, including autoantibody-mediated demyelination (pattern II) with complement involvement.\n\n## Relevance to Neurodegeneration Research\n\nMS serves as a critical model disease for understanding the mechanisms of neuroinflammation, demyelination, and neurodegeneration that have broader implications for other neurodegenerative conditions. Research into MS has illuminated fundamental pathways including the role of neuroinflammation in driving progressive neuronal loss, which shares features with [Alzheimer's Disease] and [Parkinson's Disease] pathology.\n\nThe [STING] pathway has emerged as a particularly relevant connection to MS pathology. Activation of the cyclic GMP-AMP synthase (cGAS)-STING pathway in microglia and other CNS-resident cells triggers type I interferon responses that exacerbate neuroinflammatory cascades. This pathway connects peripheral immune activation with CNS gliosis and has been implicated in driving disease progression independent of acute relapse activity.\n\nUnderstanding MS progression mechanisms has informed research into [Amyotrophic Lateral Sclerosis (ALS)], where similar neuroinflammatory pathways contribute to motor neuron degeneration. The concept of \"inside-out\" neurodegeneration—where axonal dysfunction precedes structural loss—applies to both MS and other proteinopathies. MS research has also advanced understanding of remyelination failure, which has implications for oligodendrocyte biology relevant to multiple neurodegenerative conditions.\n\n## Related Entities\n\n**Pathways and Processes:**\n- [Demyelination] - the primary pathological hallmark of MS\n- [Neurodegeneration] - progressive axonal and neuronal loss\n- [STING] signaling pathway - implicated in disease progression\n\n**Related Proteins:**\n- Myelin oligodendrocyte glycoprotein (MOG)\n- Myelin basic protein (MBP)\n- TREM2 - microglia activation marker\n- cGAS - upstream activator of STING\n\n**Associated Disease Concepts:**\n- Neuroinflammation\n- Oligodendrocyte pathology\n- Autoimmune encephalitis\n- Progressive demyelinating disease\n\n## References\n\n1. Dobson R, Giovannoni G. Multiple sclerosis: a practical guide to diagnosis and management. Lancet Neurol. 2019;18(3):269-281.\n\n2. Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742-768.\n\n3. Lassmann H. Multiple Sclerosis: lessons from neuropathology. Semin Immunopathol. 2022;44(5):649-659.\n\n4. Absinta M, Ha SK, Nair G, et al. Cortical pathology in progressive MS: a 7T MRI study. Ann Neurol. 2021;89(3):537-547.\n\n5. Lodygin D, Flügel A. Innate sensing of adaptive immunity: microglial STING gets activated. Trends Neurosci. 2020",
  "entity_type": "disease"
}

{
  "content_md": "A disease referenced in 5880 knowledge graph relationships. Key connections: causes DEMYELINATION, causes NEURODEGENERATION, implicated_in STING. Associated with 4 hypothesiss in the SciDEX knowledge base.",
  "entity_type": "disease"
}